



PROMETHEUS® Serum Infliximab/HACA Measurement

Cat. # 3130
Cat. #3120 (Serum infliximab only)

Product Description

Serum infliximab concentrations may vary among equally dosed patients. PROMETHEUS® Serum Infliximab/HACA Measurement can aid physicians in determining the dose of infliximab and guide infusion intervals. The HACA portion of the test detects human anti-chimeric antibodies (HACA / antibodies to infliximab). Patients that develop HACA may experience infusion reactions and/or a reduced duration of efficacy of infliximab. Due to the antigen-antibody effect, Prometheus recommends that HACA testing is performed after infliximab has been completely metabolized.

- A quantitative analysis of infliximab levels post infusion and a quantitative analysis of HACA levels.
- PROMETHEUS Serum Infliximab/HACA Measurement is only offered at Prometheus.
- **Specimen Requirements** - Serum, 2.0 mL: SST or Red Top Tube.
- **Shipping and Handling** - Ambient or refrigerated.
- **Storage Conditions/Stability** - 7 days.
- **Turn Around Time** - 7 business days from date of receipt.
- **Reference Range:**
 - Serum infliximab: <1.4 µg/mL
 - HACA PMT activity: <1.69 µg/mL

Facilities Description

- Prometheus is located in San Diego, CA. **Tax ID#** 33-0685754 **NPI#** 1073642641.
- Licensed in several states including New York and California.
- Prometheus Laboratories Inc. is CLIA certified and accredited by the College of American Pathologists. This test was developed and its performance characteristics determined by Prometheus Laboratories Inc. It has not been cleared or approved by the U.S. Food and Drug Administration.

CPT Codes (as applied by Prometheus)

- **83520**, Human Anti-Chimeric Antibody (HACA), Infliximab-specific ELISA
- **83520**, Serum Infliximab Level, anti-TNF ELISA

Literature References

- Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. *N Eng J Med*. 2003;348:601-608.
- St. Clair EW, Wagner CL, Fasanmade AA, et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis. *Arthrit Rheum*. 2002;46(6):1451-1459.